

Index

Please Note: Entries in *italics* refer to figures, entries in **bold** refer to tables.

8-OHdG *see* 8-hydroxydeoxyguanosine

AAb *see* autoantibodies

acellular pertussis combination vaccines, 21–22

acetylcholinesterase (AChE) inhibitors, Gulf War Syndrome, 169

AChE *see* acetylcholinesterase

ACPAs *see* anticitrullinated protein antibodies

acute lymphomas, postvaccination, 97

adaptive immunity, bisphenol A, 232–234

ADHD *see* attention deficit/hyperactivity disorder

adjuvant-induced autoimmunity, 8, 9–11, 87–88, 270–271

see also Autoimmune/Inflammatory Syndrome Induced by Adjuvants

adjuvants

classification, 16–18

definition, 15

etymology, 16

history of, 18–19

lipophilicity, 98–100, **99**

mechanisms, 19–20

safety and side effects, 20–24

see also nutritional adjuvants; *specific adjuvants...*; vaccine adjuvants

α 1AdR *see* α 1-adrenergic receptors

α 2AdR *see* α 2-adrenergic receptors

β 1AdR *see* β 1-adrenergic receptors

β 2AdR *see* β 2-adrenergic receptors

α 1AdR *see* α 1-adrenergic receptors

α 2AdR *see* α 2-adrenergic receptors

β 1AdR *see* β 1-adrenergic receptors

β 2AdR *see* β 2-adrenergic receptors

α 1-adrenergic receptors (α 1AdR), 118, 130

α 2-adrenergic receptors (α 2AdR), 130

β 1-adrenergic receptors (β 1AdR), 118

β 2-adrenergic receptors (β 2AdR), 118

ADs *see* autoimmune diseases

adult-onset Still's disease (AOSD), 202

adverse events

acetylcholinesterase inhibitors, 169

aluminum-adjuvanted vaccines, 20–22

biopolymer injections, 284–297, **285–286**

emulsion-adjuvanted vaccines, 22–23

gluten, 32, 32–33

immune checkpoint inhibitors, 192–195

mesh implants, 69–72

novel adjuvants, 23–24

pesticides, 169

vaccine adjuvants, 20–24, 86–88

AID *see* autoimmune diseases

AIRD *see* autoimmune rheumatic diseases

Akureyri disease (Iceland disease), 109

ALCL *see* anaplastic large cell lymphoma

allergic reactions, 71, 156, 306

aluminum, 7, 8, 100, 203–205, 207, 209–210, 214

aluminum-adjuvanted vaccines, **16**, 17, 20–22, 98–101, **99**, 270–271

ALVAL *see* aseptic lymphocytic (lymphocyte-dominated) vasculitis-associated lesions

ANA *see* antinuclear antibodies

analogy, 81

anaplastic large cell lymphoma (ALCL), 4, 97, 100–101

ANCAs *see* antineutrophil cytoplasmic antibodies

animal models, 93–96, 120–122, 169–170, 256, 312–313

ANS *see* autonomic nervous system

anthrax vaccines, 170–171

anti-angiotensin II type 1 receptor (anti-AT1R) autoantibodies, 119–120

anti-AT1R *see* anti-angiotensin II type 1 receptor

anti-bisphenol A antibodies, 235

anticitrullinated protein antibodies (ACPAs), 206

anti-endothelin receptor type A (anti-ETAR) autoantibodies, 120

anti-ETAR *see* anti-endothelin receptor type A

antigen-presenting cells (APCs), bisphenol A, 230–231

anti-GPCR antibodies, 117–127, **121**, 130–131

anti-idiotypic immune responses, 9–10

anti M3 receptor autoantibodies, 120

antimony, 203, 211

antineutrophil cytoplasmic antibodies (ANCAs), 100

antinuclear antibodies (ANA), 131, 172, 193

antiphospholipid syndrome (APS), 131, 237

AOSD *see* adult-onset Still's disease

APCs *see* antigen-presenting cells

apoptosis-associated speck-like protein containing a C-terminal caspase-recruitment domain (ASC), 75

Autoimmune Disorders: Adjuvants and Other Risk Factors in Pathogenesis, First Edition.

Edited by Abdulla Watah, Nicola Luigi Bragazzi, and Yehuda Shoenfeld.

© 2024 John Wiley & Sons Ltd. Published 2024 by John Wiley & Sons Ltd.

Index

- APRIL ligand, 202
APS *see* antiphospholipid syndrome
arthralgia, immune checkpoint inhibitors, 192
arthritis *see* inflammatory arthritis; rheumatoid arthritis
AS03-adjuvanted vaccines, **16**, 17, 99
ASC *see* apoptosis-associated speck-like
 protein containing a C-terminal caspase-
 recruitment domain
aseptic lymphocytic (lymphocyte-dominated) vasculitis-
 associated lesions (ALVAL), 76
ASIA *see* Autoimmune/inflammatory Syndrome Induced
 by Adjuvants
ASIA-MO *see* Autoimmune/inflammatory Syndrome
 Induced by Adjuvants, mineral oils
atezolizumab (Tecentriq), 192
atopic diseases, mesh-mediated disease, 71
attention deficit/hyperactivity disorder (ADHD), 36–37
atypical poliomyelitis, 109
auramine O, 36
autoantibodies (AAb), 117–127, **121**, 130–131, 139, 172,
 193, 253–254
autoimmune diseases (ADs/AID)
 animal models, 93–96
 development, 73–76, 74
 foreign bodies, 3–4, 73–76
 genetics, 7–9
 immune checkpoint inhibitors, 194–195
 and intestinal permeability, 306–307
 lymphoproliferative disorders, 4, 93–96
 metals, 3–4, 201–223, 337–340
 postvaccination, 8–11, 87–88, 170–171
 POTS associations, 131–132
 relative lymphomagenic risks, 93, **94**
 see also specific diseases...
autoimmune dysautonomia, 63–66, 117–127, **123**,
 139–140, **139**
autoimmune exocrinopathy, 120
Autoimmune/inflammatory Syndrome Induced by
 Adjuvants (ASIA), 7–14, **8**, 72–76, **76**, **92**, 93–96,
 112–113, 213–214, 305–321
autoimmune rheumatic diseases (AIRD), 181–190
autoimmune sialadenitis, 202–203
autonomic nervous system (ANS), 117–127
avelumab (Bavencio), 192
azathioprine, 256
AZB *see* azoximer bromide
azo food dyes, 36
azoximer bromide (AZB/polyoxidonium), 23–24

bacterial-derived adjuvants, **16**, 17
Bavencio *see* avelumab
 β 1-adrenergic receptors (β 1AdR), 118
 β 2-adrenergic receptors (β 2AdR), 118
biomarkers, Gulf War Syndrome, 171–172
biomaterials *see specific materials...*
biopolymer injections, 283–303
biopsy, small-fiber neuropathy, 140
bisphenol A (BPA), 225–246
 adaptive immunity, 232–234
 as an adjuvant, 227
 antibodies, 235
 autoimmunity, 228–240
 direct mechanisms, 228–234
 endocrine disruption, 225–227, 235–236
 epigenetic alterations, 236
 healthcare exposures, 227
 humoral immunity, 234
 indirect mechanisms, 234–236
 innate immunity, 228–232
 pathophysiology, 225–241
 protein disulfide isomerase, 234–235
BPA *see* bisphenol A
Bradford–Hill criteria, 78–80
brain defects, Gulf War Syndrome, 171
BRI *see* building-related illness
building-related illness (BRI), 156
 see also sick building syndrome
butterfly wings technique, 295

cadmium, 204–208, 210, 211, 212
CaHA *see* calcium hydroxyapatite
calcinosis cutis, 204
calcium hydroxyapatite (CaHA), **285**
Canadian consensus criteria, chronic fatigue
 syndrome, 111
cancer, immune checkpoint inhibitors, 191–199
caramel color class IV, 36
carbamates, Gulf War Syndrome, 169
CARD *see* caspase-recruitment domains
cardiac autoimmunity, 239
caspase-recruitment domains (CARD), 75
causation
 analogy, 80
 Bradford–Hill criteria, 78–80
 coherence, 80
 consistency, 80
 experimental evidence, 80
 Gulf War Syndrome, 168–171
 Koch’s postulates, 78
 mesh-mediated disease, 78–81
 sarcoidosis, 248–249, **250**
 sick building syndrome, 156–159
 temporality, 80
 see also etiology; pathophysiology
CD *see* celiac disease
cecal ligation and puncture model (CLP), 312–313
celiac disease (CD), 32–34, 131
cellular immunity, bisphenol A, 228–234
cemiplimab (Libtayo), 192
central nervous system (CNS) alterations, Gulf War
 Syndrome, 171
central sensitivity syndrome, 112
cerebral blood flow, Gulf War Syndrome, 171
CFA *see* complete Freund’s adjuvant
CFS *see* chronic fatigue syndrome
challenge-dechallenge-rechallenge evidence, mesh, 79–80
chemical warfare agents, 169–170
childhood stress, 309
cholinergic neurotransmission, 120
chromium, systemic lupus erythematosus, 206
chronic Epstein–Barr virus syndrome, 110
chronic fatigue syndrome (CFS), 70, 107–115,
 122, 173, 338
chronic inflammation
 animal models, 312–313
 Gulf War Syndrome, 170, 171–172

- lymphoproliferative disorders, 4, 91–106
- mesh, 2–4, 73–76
- metals, 3–4
- neurogenic switching, 162
- POTS, 131
- programmed cell death protein-1 95–96
- self-reactive clones, 101
- silicone breast implants, 2, 3–4, 53–54
- Chronic Multisystem Illness (CMI), 167
 - see also* Gulf War Syndrome
- classification
 - chronic fatigue syndrome, 108–112
 - small-fiber neuropathy, 140
 - vaccine adjuvants, 16–18
- claudins, 307–308
- cleaning agents, 308
- clioquinol, 209
- clone immunodominancy, 96
- CLP *see* cecal ligation and puncture model
- CMI *see* Chronic Multisystem Illness
- CMV *see* cytomegalovirus
- CNS *see* central nervous system
- coherence, 80
- colchicine, 295–297
- colitis, 35, 36
- collagen injections, **285**
- combination vaccines, 21–22, 88, 186
- complete Freund's adjuvant (CFA), 99
- components, tattoos, 148–149
- consistency, 80
- conventional buildings, sick building syndrome, 159
- copper, 204–210, 212
- cortical thymocyte marker of *Xenopus* (CTX), 307
- corticosteroids, 196, 256
- Coxsackie B3 virus, 239
- CpG hypomethylation, 236
- CpG oligodeoxynucleotides (ODNs), **16**, 17
- Crohn's disease, 37
- cross-linked nanoparticles, 35
- cross-reactivity, 10
- CTLA-4 *see* cytotoxic T lymphocyte antigen-4
- CTX *see* cortical thymocyte marker of *Xenopus*
- cuprizone, 208–209
- cyclophosphamide, 122
- cyclosarin, 169
- CYP P450 inhibition, 236
- cytokine-based adjuvants, 18
- cytomegalovirus (CMV), 107, 269
- cytotoxic T lymphocyte antigen-4 (CTLA-4), 95–96, 191–192
- damage-associated molecular patterns (DAMPs), 232
- DAMPs *see* damage-associated molecular patterns
- delivery systems, classification, 18
- dental implants, 337–340
- depression, 120, 169
- dermatopolymyositis, influenza vaccination, 183–184
- detergents, 308
- dextran sulfate sodium (DSS)-induced colitis, 35
- diagnosis
 - ASIA, **76**, **92**
 - chronic fatigue syndrome, 107–108, 111
 - Gulf War Syndrome, 168–173
 - mesh-mediated disease, 72
 - mineral oil reactions, 330–331
 - postural orthostatic tachycardia syndrome, 131–132
 - sarcoidosis, 248–253
 - small-fiber neuropathy, 140–142, **141**
- differential diagnosis, postural orthostatic tachycardia syndrome, 131–132
- diffuse large B-cell lymphoma (DLBCLs), 94, 273
- diisopropyl fluorophosphate, 169–170
- diphtheria combination vaccines, 21–22, 88, 186
- direct mechanisms, bisphenol A, 228–234
- DLBCLs *see* diffuse large B-cell lymphoma
- DSS *see* dextran sulfate sodium
- durvalumab (Imfinzi), 192
- dysautonomia, 63–66, 117–127, 139–140, **139**
 - animal models, 120–122
 - clinical associations, 118–120, **121**
 - genetic susceptibility, 120, **123**
 - historical perspectives, 117–118
 - treatment, 122–123
- EAE *see* experimental autoimmune encephalomyelitis
- early-life stress, 309–310
- EBV *see* Epstein–Barr virus
- effort syndrome, 108–109
- emulsifiers, 31, 37–38, 100, 308
- emulsion-adjuvanted vaccines, **16**, 17, 22–23, 37–38
- endocrine autoimmunity, bisphenol A, 237–239
- endocrine disruption, bisphenol A, 225–227, 235–236
- environmental factors, 305–321
 - epithelial tight junctions, 307–309
 - Gulf War Syndrome, 168
 - gut–brain axis, 310–312
 - intestinal permeability, 306–307
 - microplastics, 308–309
 - sarcoidosis, 248–249, **250**
 - Sjögren's syndrome, 266–267
 - stress, 309–310
- epidemiology
 - ASIA clinical manifestations, **161**
 - chronic fatigue syndrome, 107
 - Gulf War Syndrome, 167–168, **174**
 - lymphomas and autoimmune diseases, 93, **94**
 - mineral oils, 324–325
 - sick building syndrome, **157**
- epigenetic alterations, 211, 236
- epithelial tight junctions, 307–309, 311
- epitope breadth, 96
- Epstein–Barr virus (EBV), 4, 107, 110, 119, 268
- ERs *see* estrogen receptors
- estrogen receptors (ERs), 225–228, 235–236
- etiology
 - foreign body reactions, 73–76
 - Gulf War Syndrome, 168–171
 - mesh-mediated disease, 72–76, 78–81
 - mineral oils, 325–326
 - sarcoidosis, 247–248, **250**
 - sick building syndrome, 156–159
 - silicone implant incompatibility syndrome, 52, 53
 - small-fiber neuropathy, **136**, 137–139
 - see also* pathophysiology

Index

- experimental autoimmune encephalomyelitis (EAE), 209
explantation
 biopolymers, 290–297, **291–294**
 silicone breast implants, 56–57
- fatigue, 70, 168
 see also chronic fatigue syndrome
FBR *see* foreign body reactions
Febricula, 108
ferroptosis, 35
FGFR-3 *see* fibroblast growth factor receptor-3
fibroblast growth factor receptor-3 (FGFR-3)
 autoantibodies, 139
fibromyalgia (FM), 118–119, 120–123, 173, 184, 338
fillers, 283–303, **285–286**, **291–294**, 323–336
Fluad®R vaccine, 22–23
FM *see* fibromyalgia
food additives, 29–50, 39, **40**
food colorants, 31–32, 36–37
food emulsifiers, 31, 37–38
foreign body reactions (FBR), 73–76, 97–100, 143–144, 147–153, 284–297
 see also mesh implants; silicone breast implants
Fukuda definition, chronic fatigue syndrome, 111
- GAD *see* glutamic acid decarboxylase
gastrointestinal disease, 71, 120, 239–240
GBS *see* Guillain–Barré syndrome
GCS *see* glucocorticosteroids
genetic susceptibility, 7–9
 autoimmune dysautonomia, 120, **123**
 celiac disease, 33, 34
 chronic fatigue syndrome, 112
 emulsifier sensitivity, 38
 Gulf War Syndrome, 171, 173
 nanoparticle sensitivity, 35
 sarcoidosis, 254
 silicone implant incompatibility syndrome, 8, 54–55
 Sjögren's syndrome, 265
genomic instability, 95
gliadins, 32–33
glucocorticoids, 309–310
glucocorticosteroids (GCS), 256
glutamic acid decarboxylase (GAD) vaccines, 205
gluteal biopolymer injections, 283–303, **291–294**
gluten, 30, 32–33
gold alloys, 338
G-protein-coupled receptors (GPCRs), 117–123, **121**, 130–131, 311
Graves' disease, 117–118
green buildings, sick building syndrome, 159
Guillain–Barré syndrome (GBS), 8, 98
Gulf War Syndrome (GWSy), 8, 167–180, **174**
gut–brain axis, 310–312
gut microbiomes, 172, 210, 235, 310–312
gut permeability, 32, 33, 34, 38, 306–307
GWSy *see* Gulf War Syndrome
- H1N1 vaccinations, 8–9, 10
Haemophilus influenzae (*H. influenzae*) vaccines, 22–23
Hashimoto's disease, 186
HBV *see* hepatitis B
HCV *see* hepatitis C virus
heart rate variability (HRV) testing, **141**, 142
heavy metals, 7, 8, 100, 201–223, 337–340
 see also specific elements...
helper T-cells, bisphenol A, 232–234
hematologic malignancies, 97–101
 see also foreign body reactions
hepatitis B (HBV) vaccines, 22, 88, 184–185
hepatitis C virus (HCV), 268–269
HHV-6 *see* human herpes virus
H. influenzae *see* *Haemophilus influenzae*
histopathology, mineral oil reactions, 331
HLA *see* human leukocyte antigen
hormonal disruption, 225–227, 235–239, 272–273
household cleaning agents, 308
HPV *see* human papilloma virus
HRV *see* heart rate variability
HTLV-1 *see* human T-cell leukemia virus
human herpes virus (HHV-6), 107, 119
human papilloma virus (HPV) vaccines, 88, 131, 185–186
human T-cell leukemia virus (HTLV-1), 268, 269
humoral disturbances, Gulf War Syndrome, 172
humoral immunity, 234
hyaluronic acid, **285**, 323–336
hydroxychloroquine, 256
8-hydroxydeoxyguanosine (8-OHdG), 156
- IA *see* inflammatory arthritis
IBD *see* inflammatory bowel disease
Iceland disease *see* Akureyri disease
ICIs *see* immune checkpoint inhibitors
ID *see* intradermal
idiopathic environmental intolerance (IEI), 156
idiopathic thrombocytopenic purpura (ITP), 8, 88
IEI *see* idiopathic environmental intolerance
IEQ *see* indoor environmental quality
IFA *see* incomplete Freund's adjuvant
ILCs *see* innate lymphoid cells
IM *see* intramuscular
imaging studies, mineral oil reactions, 330–331
Imfinzi *see* durvalumab
immune checkpoint inhibitors (ICIs), 191–199, 271–272
immune hyperstimulation, 1–6, 73–76, 202–203, 265, 266–267, 273–274
immune-modulatory antibodies, 191–199
 see also immune checkpoint inhibitors
immune potentiators, **16**, 17
immune related adverse events (irAEs), 191–199
immunodominant clones, 96
immunostimulatory complexes (ISCOMS), 99
immunosuppressive therapy, sarcoidosis, 254–256
inactivated polio vaccine (IPV), 21–22
incomplete Freund's adjuvant (IFA), 99
indirect mechanisms, bisphenol A, 234–236
indoor environmental quality (IEQ), 155–166
 see also sick building syndrome
inflammasomes, 75, 97, 203, 267
inflammatory arthritis (IA), 193
inflammatory bowel disease (IBD), 32, 35, 37, 71, 209–210
influenza vaccines, 22–23, 88, 182–184
innate immunity, 228–232

- innate lymphoid cells (ILCs), 231
 instrumental methods, 140–142, **141**
 Intanza® vaccine, 22–23
 interleukin-based adjuvants, 18
 intestinal permeability, 306–307
 intradermal (ID) vaccines, 22–23
 intramuscular (IM) vaccines, 22–23
 intravenous immunoglobulin (IVIG), 122–123, 196
in vitro effects, biopolymers, 284
 ipilimumab (Yervoy), 192
 IPV *see* inactivated polio vaccine
 irAEs *see* immune related adverse events
 ISA 51 *see* Montanide ISA*TM51
 ischemic cerebral disease, 70
 ISCOMS *see* immunostimulatory complexes
 ITP *see* idiopathic thrombocytopenic purpura
 IVIG *see* intravenous immunoglobulin
- kaleidoscope phenomenon, 94
 Keytruda *see* pembrolizumab
 Koch's postulates, 78
- laboratory testing, 72, 140, 330
 laser evoked potentials, **141**
 LD-SFN *see* length-dependent small-fiber neuropathy
 lead, 203, 210, 211
 leflunomide, 256
 legislation, 159–160
 see also regulation
 length-dependent small-fiber neuropathy (LD-SFN), 140
 Libtayo *see* cemiplimab
 lindane *see* organochlorine
 lipid particles, **16**, 17
 lipid sorting, 98
 lipophilicity, adjuvants, 98–100, **99**
 lipopolysaccharide (LPS), 99, 312
 liposomes, **16**, 17
 liquid silicone, **285**
 livedo reticularis, mesh-mediated disease, 70
 liver function, bisphenol A, 236
 LPS *see* lipopolysaccharide
 lymph nodes, 70
 lymphomagenesis, 91–106, 273–274
 lymphoproliferative disorders, 4, 72, 91–106, **94**, 273–274
- mAChR *see* muscarinic acetylcholine receptors
 macrophagic myofasciitis syndrome (MMF),
 7, 8, 100, 214
 MALT *see* mucosa-associated lymphoid tissue lymphomas
 manganese, thyroid disease, 212
 MAPK *see* mitogen activated protein kinase
 MCS *see* multiple chemical sensitivity
 ME *see* myalgic encephalomyelitis
 measles–mumps–rubella (MMR) vaccinations, 88
 memory responses, foreign body reactivity, 75–76
 Mentanil Yellow, 36
 mercury, 203, 212, 337–338
 mesh implants, 2–4, 67–84, 75
 metals, 7, 8, 100, 148–149, 201–223, 337–340
 see also specific elements...
 methotrexate, 256
 methylation, 101
- MF59-adjuvanted vaccines, 17, 22–23, 99
 MGB *see* microbiota-gut-brain
 microbial-derived adjuvants, **16**, 17
 microbial transglutaminase (mTG), 31, 33–34
 microbiome, 172, 210, 235, 310–312
 microbiota-gut-brain (MGB) axis, 310–312
 microparticles, **16**, 17
 microplastics, 308–309
 migration, silicone gel particles, 2
 mineral oil aromatic hydrocarbons (MOAH), 325–326
 mineral oils, 323–336
 mineral oil saturated hydrocarbons (MOSH), 325–326
 mineral salts, **16**, 17, 21–22
 mitogen activated protein kinase (MAPK), 202–203
 MMF *see* macrophagic myofasciitis syndrome
 MMR *see* measles–mumps–rubella
 MOAH *see* mineral oil aromatic hydrocarbons
 models
 sarcoidosis, 256
 see also animal models
 molecular mimicry, 10, 225–227, 235–236
 monophosphoryl lipid A (MPL-A), **16**, 17, 99
 Montanide ISA*TM51 (ISA 51) vaccine, 23
 MOSH *see* mineral oil saturated hydrocarbons
 MPL-A *see* monophosphoryl lipid A
 MS *see* multiple sclerosis
 mTG *see* microbial transglutaminase
 mucosa-associated lymphoid tissue lymphomas
 (MALT), 93–94
 mucosal adjuvants, **16**, 17
 multiple chemical sensitivity (MCS), 156, 173
 multiple sclerosis (MS), 131, 207–209
 muscarinic acetylcholine receptors (mAChR),
 118, 130
 myalgia, 192–193
 myalgic encephalomyelitis (ME), 110, 119–120, 122
 see also chronic fatigue syndrome
 MyD88 pathway, 202–203
 myocarditis, 239
 myositis, 194
- nAChR *see* nicotinic acetylcholine receptors
 nanoemulsions, 37–38
 nanoparticles (NPs), **16**, 17, 31, 34–36
 narcolepsy, 8–9, 10
 NCA *see* neurocirculatory asthenia
 neoplasms, and sustained immune activation, 273–274
 nerve agents, and Gulf War Syndrome, 169–170
 NETs *see* neutrophil extracellular traps
 neurocirculatory asthenia (NCA), 108–109
 neurogenic switching, 162
 neuroinflammation, 171
 neurological syndromes, 70, 168, 169–171, 194, 240
 neutrophil extracellular traps (NETs), 231
 NHL *see* non-Hodgkin lymphomas
 nickel, 204–207
 nicotinic acetylcholine receptors (nAChR), 130
 night sweats, mesh-mediated disease, 70
 nivolumab (Opdivo), 192
 NLD-SFN *see* non-length-dependent small-fiber
 neuropathy
 NLRP3 *see* NOD-like receptor protein 3

Index

- NOD-like receptor protein 3 (NLRP3) inflammasomes, 75, 97, 203, 267
- non-Hodgkin lymphomas (NHL), 93–94
- non-length-dependent small-fiber neuropathy (NLD-SFN), 140
- novel adjuvants, 23–24
- NPs *see* nanoparticles
- nutritional adjuvants, 29–50
- and ASIA, 29–30, 39, **40**
 - emulsifiers, 31, 37–38
 - food colorants, 31–32, 36–37
 - gluten, 30, 32–33
 - increasing usage, 30
 - microbial transglutaminase, 31, 33–34
 - nanoparticles, 31, 34–36
- occludin, 307–308
- ODNs *see* CpG oligodeoxynucleotides
- oil adjuvants, 37–38, 99–100, **99**
- see also* mineral oils
- OP *see* organophosphates
- Opdivo *see* nivolumab
- Orange II, 36
- organochlorine (lindane), 169
- organophosphates (OP), 169, 173
- organ-specific events, immune checkpoint inhibitors, 195
- oxidative stress, 76, 95, 232
- pain, 70, 168
- palladium, systemic sclerosis, 211
- p*-anilinoaniline, 36
- paraffin, **285**
- paraoxonase, 173
- pararosaniline, 36
- parvovirus B19, 107
- pathophysiology
- ASIA, 9–11
 - autoimmune dysautonomia, 117–122
 - bisphenol A, 225–241
 - emulsifiers, 37–38
 - food colorants, 36–37
 - foreign body reactions, 73–76, 75
 - gluten, 32
 - Gulf War Syndrome, 8, 171–172
 - mesh-mediated disease, 73–76, 75
 - microbial transglutaminase, 33
 - mineral oils, 326–328
 - nanoparticles, 34–35
 - postvaccination syndromes, 9–11
 - silicone breast implants, 53–54, 63–64
 - small-fiber neuropathy, **136**, 137–139
- pattern recognition receptors (PRRs), 20, 75–76, 202–203
- PB *see* pyrostigmine bromide
- PCI *see* peritoneal contamination and infection
- PD-1 *see* programmed cell death protein-1
- PDI *see* protein disulfide isomerase
- PDMS *see* polydimethylsiloxane
- Pediarix® vaccine, 21–22
- pembrolizumab (Keytruda), 192
- Pentacel® vaccine, 22
- Pentaxim® vaccine, 22
- peripheral immune abnormalities, Gulf War Syndrome, 172
- peritoneal contamination and infection (PCI) model, 312
- pesticides, Gulf War Syndrome, 168–169
- phagocytosis, bisphenol A, 229–230
- pharmacokinetics, adjuvant lipophilicity, 98–100, **99**
- plastics, 308–309
- plausibility, mesh-mediated disease, 78
- PLGA *see* polyethylenimine-coated poly lactic-co-glycolic acid
- PLLA *see* poly-L-lactic acid
- PMMA *see* polymethyl methacrylate
- PMR *see* polymyalgia rheumatica
- pneumococcal vaccinations, 184
- poliovirus vaccines, 21
- polyacrylamide hydrogels, **285**
- polydimethylsiloxane (PDMS), 101
- polyethylenimine-coated poly lactic-co-glycolic acid (PLGA) nanoparticles, 35
- poly-L-lactic acid (PLLA), **286**
- polymethyl methacrylate (PMMA), **286**
- polymyalgia rheumatica (PMR)-like syndromes, immune checkpoint inhibitors, 193
- polyneuropathic small-fiber neuropathy, 140
- polyoxonium *see* azoximer bromide
- polypropylene (PP) mesh, 2–4, 67–84, 75
- postinfection conditions, 118–119, 267–270
- posttranslational modification of proteins (PTMP), 33
- postural orthostatic tachycardia syndrome (POTS), 108, 112, 118–120, 122, 129–135, 150
- postvaccination acute lymphomas, 97
- postvaccination autoimmunity, 7–11, 87–88, 100, 118–119, 170–171, 214
- POTS *see* postural orthostatic tachycardia syndrome
- PP *see* polypropylene
- pregnancy, 205
- premature ovarian failure, 238
- prenatal stress (PRS), 309–310, 313
- prevalence
- ASIA clinical manifestations, **161**
 - Gulf War Syndrome, 167–168, **174**
 - immune checkpoint inhibitor reactions, 192–195
 - sick building syndrome, **157**, **161**
- pristane, 99, 213
- pristane *see* tetramethylpentadecane
- programmed cell death protein-1 (PD-1), 95–96, 192
- protein disulfide isomerase (PDI), 234–235
- protein fragmentation, 211
- PRRs *see* pattern recognition receptors
- PRS *see* prenatal stress
- PTMP *see* posttranslational modification of proteins
- pyrethroids, Gulf War Syndrome, 169
- pyrexia, mesh-mediated disease, 70
- pyrostigmine bromide (PB), and Gulf War Syndrome, 170
- QS-21 adjuvant, 99
- QSART *see* quantitative ship motor axon reflex testing
- QST *see* quantitative sensory testing
- quadrivalent human papilloma virus vaccines, 88, 131, 185–186
- quantitative sensory testing (QST), **141**, 142

- quantitative ship motor axon reflex testing (QSART), **141**, 142
- questionnaires, small-fiber neuropathy, 140
- RA *see* rheumatoid arthritis
- radiological assessments, 72
- reactive oxygen species (ROS), 76, 95, 232
- Red 40, 36
- regulations, 88–89, 159–160
- regulatory T cells (Treg), 95
- removal
- mineral oils, 332–333
 - silicone breast implants, 56–57
- rheumatoid arthritis (RA), 8, 120, 183, 184, 185, 206–207
- rhodamine B, 36
- rituximab, 94, 122
- ROS *see* reactive oxygen species
- Royal Free disease, 109
- Saccharomyces cerevisiae*, 269
- safety
- aluminum-adjuvanted vaccines, 20–22
 - emulsion-adjuvanted vaccines, 22–23
 - novel adjuvants, 23–24
 - pesticides, 169
 - vaccine adjuvants, 20–24, 86–89
- see also* adverse events
- sarcoidosis, 142–143, 149, 195, 247–264, 250, **250–251**
- sarin, 169
- SARS-CoV-2 9, 10–11, 119, 120, 270
- SBI *see* silicone breast implants
- SBS *see* sick building syndrome
- SCFAs *see* short-chain fatty acids
- self-adjuvating lipopeptide vaccines, 37
- self-reactive clones, and lymphomagenesis, 101
- semivolatile organic compounds (SVOCs), 157, 159
- sensory symptoms, small-fiber neuropathy, 139–140, **139**
- serological assessments, 72, 140, 171–172
- SFN *see* small-fiber neuropathy
- Shoenfeld's syndrome *see* Autoimmune/inflammatory Syndrome Induced by Adjuvants
- short-chain fatty acids (SCFAs), 311
- Sicca syndrome, 193–194, 265–266, 269
- see also* Sjögren's syndrome
- sick building syndrome (SBS), 155–166, **157**, **161**
- side effects *see* adverse events
- SIGBIC *see* silicone-induced granuloma of the breast implant capsule
- SIIS *see* silicone implant incompatibility syndrome
- silica nanoparticles, 34–35
- silicone, 53, 100, **285**
- silicone breast implants (SBIs), 2, 3–4, 8, 51–66, 63–66, 100–101, 118, 120, **121**, 143–144, 271
- silicone implant incompatibility syndrome (SIIS), 51, 54–62, 101, 143–144, 150
- silicone-induced granuloma of the breast implant capsule (SIGBIC), 4
- silicosis, 271
- silver, 204–205
- SIR *see* standard incidence ratios
- Sjögren's syndrome (SjS/SS), 70, 93, 101, 120, 122, 131, 143, 149, 193–194, 202–203, 213, 237, 265–281, 271, 272
- as ASIA, 266
 - immune hyperstimulation, 266–267
 - postinfection, 267–270
 - vaccinations, 270–271
- SjS *see* Sjögren's syndrome
- SLE *see* systemic lupus erythematosus
- sleep disorders, 120, 168
- small-fiber neuropathy (SFN), 132, **136**, 137–146, **141**, 150, 250, **251**
- smoking, 206
- specificity of association, 80
- sphingomyelins, 98
- squalene, 99, 170–171
- squalene nanoemulsions, 37
- stress, 309–310, 313
- subjective night sweats, 70
- superoxide dismutase, 201
- surfactants, 31, 37–38, 308
- surgical resections, 295, 332–333
- sustained immune activation, and lymphomagenesis, 91–106
- SVOCs *see* semivolatile organic compounds
- systemic lupus erythematosus (SLE), 8, 88, 120, 131, 182–186, 195, 202–205, 237
- systemic sclerosis, 120, 122, 211
- systemic symptoms, mesh implants, 70–71
- systems vaccinology, 20
- T1DM *see* type 1 diabetes mellitus
- TAMPs *see* tight junction-associated MARVEL proteins
- Tapanui outbreak, 110
- tartrazine, 36
- tattoos, 147–153
- T-cells, 95–96, 232–234
- Tecentriq *see* atezolizumab
- temporality, 80
- testosterone, 272
- tetanus combination vaccines, 21–22, 186
- tetramethylpentadecane (pristane), 99, 213
- Theiler's virus induced demyelination (TVID), 240
- thrombotic thrombocytopenia, 10–11
- thyroid disease, 211–212, 238
- tight junction-associated MARVEL proteins (TAMPs), 307
- titanium dioxide, 35
- Toll-like receptor 4 (TLR4), 4, 75–76
- Toll-like receptor (TLR) agonists, **16**, 17
- TPSO *see* transporter protein
- transient reporter potential channel VI (TRPV1), 74
- transporter protein (TPSO), 171
- treatment
- autoimmune dysautonomia, 122–123
 - biopolymer injection events, 290–297, **291–294**
 - immune checkpoint inhibitor side effects, 195–196
 - mineral oil reactions, 331–333
 - postural orthostatic tachycardia syndrome, 132
 - sarcoidosis, 255–256
 - small-fiber neuropathy, 142
 - tattoo-induced ASIA, 150

Index

- Treg *see* regulatory T cells
trisulfated heparin disaccharide (TS-HDS)
 autoantibodies, 139
TRPV1 *see* transient reporter potential channel VI
TS-HDS *see* trisulfated heparin disaccharide
TVID *see* Theiler's virus induced demyelination
type 1 diabetes mellitus (T1DM), 205–206, 238–239

urinary 8-hydroxydeoxyguanosine, 156

vaccinations, 85–89, 97, 170–171, 181–190, 270–271
 see also specific vaccines...
vaccine adjuvants, 15–27, 37–38, 86–89, 97–100, **99**
vaccine-induced immune thrombotic thrombocytopenia
 (VITT), 10–11
vaccinosis, 86–88
 see also vaccinations
vagal tone, 310–311

vascular complications, 70, 194–195
vasculitis, 194
virus-like particles (VLPs), **16**, 17
VITT *see* vaccine-induced immune thrombotic
 thrombocytopenia
VLPs *see* virus-like particles
VOCs *see* volatile organic compounds
volatile organic compounds (VOCs), 157, 159

World Trade Center attack, 10

xanthene food dyes, 36

Yellow 6, 36
Yervoy *see* ipilimumab

zinc, 211–212, 211–213

